Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab
Phase 2
Completed
- Conditions
- Age Related Macular DegenerationDiabetic Retinopathy
- Interventions
- Registration Number
- NCT00864838
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
- Diagnosis of age related macular disease or diabetic retinopathy
- Able and willing to provide informed consent
Exclusion Criteria
- History of ocular hypertension or glaucoma
- High Myopes (> 6 spherical diopters)
- High Hyperopes (> 4 spherical diopters)
- Pulmonary disease
- Renal disease
- Known allergy to any component of the study drug
- Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Acetazolamide Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection 3 Brimonidine tartarate topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection 4 Anterior chamber paracentesis anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
- Primary Outcome Measures
Name Time Method Intraocular pressure (mmHg) 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI
- Secondary Outcome Measures
Name Time Method